Verastem

AACR 2020 – Verastem reveals the logic behind its Kras deal

A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.

AACR 2020 preview – no Tigit, but plenty of novel mechanisms

Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.

January 09, 2020

Verastem plays the Kras card

For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.

August 30, 2018

Seeking alpha in PI3K inhibition

Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.

December 14, 2017

Ash 2017 winners and losers – Déjà vu

November 02, 2017

Ash 2017 preview – Blueprint and Stemline celebrate

September 15, 2017

Snippet roundup: Bad news for Sage and Santhera, good tidings for Glaxo and Bayer

September 08, 2017

Snippet Roundup: PI3Ks not dead, but PD(L)-1 multiple myeloma hopes falter

September 08, 2017

Esmo 2017 – Roche’s Lorelei gives PI3K agents another second chance

June 12, 2017

Interview – German Merck doubles down on dual-acting cancer agents

November 04, 2016

Snippet roundup: Infinity sells duvelisib, Celldex buys Kolltan and Zimmer Biomet has supply woes

Load More